{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:13:02Z","timestamp":1792059182590,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T00:00:00Z","timestamp":1473033600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12894-016-0174-2","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T13:04:16Z","timestamp":1473080656000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Stephanie C.","family":"Kn\u00fcpfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike M.","family":"Averhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten M.","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"J\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz F.","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,5]]},"reference":[{"issue":"3","key":"174_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1464-410X.2009.08371.x","volume":"103","author":"KS Coyne","year":"2009","unstructured":"Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103(3):4\u201311.","journal-title":"BJU Int"},{"key":"174_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fncel.2015.00124","volume":"9","author":"M Chin-Chan","year":"2015","unstructured":"Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci. 2015;9:124.","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"174_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mds.20867","volume":"21","author":"K Winge","year":"2006","unstructured":"Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21(6):737\u201345.","journal-title":"Mov Disord"},{"issue":"5","key":"174_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/nau.20260","volume":"25","author":"T Ogawa","year":"2006","unstructured":"Ogawa T, Seki S, Masuda H, Igawa Y, Nishizawa O, Kuno S, Chancellor MB, De Groat WC, Yoshimura N. Dopaminergic mechanisms controlling urethral function in rats. Neurourol Urodyn. 2006;25(5):480\u20139.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"174_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0028-3908(93)90151-R","volume":"32","author":"N Yoshimura","year":"1993","unstructured":"Yoshimura N, Mizuta E, Kuno S, Sasa M, Yoshida O. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology. 1993;32(4):315\u201321.","journal-title":"Neuropharmacology"},{"issue":"1","key":"174_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/1520-6777(2001)20:1<105::AID-NAU12>3.0.CO;2-9","volume":"20","author":"S Seki","year":"2001","unstructured":"Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson KE. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn. 2001;20(1):105\u201313.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"174_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/nau.20371","volume":"26","author":"CJ Fowler","year":"2007","unstructured":"Fowler CJ. Update on the neurology of Parkinson\u2019s disease. Neurourol Urodyn. 2007;26(1):103\u20139.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"174_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/nau.20054","volume":"23","author":"K Winge","year":"2004","unstructured":"Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson\u2019s disease. Neurourol Urodyn. 2004;23(7):689\u201396.","journal-title":"Neurourol Urodyn"},{"key":"174_CR9","unstructured":"Pannek JBB, Castro-Diaz D, Del Popolo G, Groen J, Karsenty G, Kessler TM, Kramer G, Str\u00f6hrer M. EAU guidelines on neuro-urology. 2014."},{"issue":"11","key":"174_CR10","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/j.1742-1241.2008.01849.x","volume":"62","author":"GG Kay","year":"2008","unstructured":"Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62(11):1792\u2013800.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"174_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/ana.10806","volume":"55","author":"C Seif","year":"2004","unstructured":"Seif C, Herzog J, van der Horst C, Schrader B, Volkmann J, Deuschl G, Juenemann KP, Braun PM. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004;55(1):118\u201320.","journal-title":"Ann Neurol"},{"issue":"6","key":"174_CR12","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131\u20139.","journal-title":"J Urol"},{"key":"174_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF03033927","volume":"9","author":"A AGaB","year":"2006","unstructured":"A AGaB. Neurophysiological effects of otulinumtoxin type A. Neurotox Res. 2006;9:109\u201314.","journal-title":"Neurotox Res"},{"issue":"1","key":"174_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.urology.2013.09.017","volume":"83","author":"RU Anderson","year":"2014","unstructured":"Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson\u2019s disease. Urology. 2014;83(1):22\u20137.","journal-title":"Urology"},{"issue":"4","key":"174_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","volume":"182","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson\u2019s disease and multiple system atrophy. J Urol. 2009;182(4):1453\u20137.","journal-title":"J Urol"},{"key":"174_CR16","unstructured":"Blok B PJ, Castro Diaz D, del Popolo G, Groen J, Gross T, Hamid R, Karsenty D, Kessler TM, Schneider MP, \u2019t Hoen L. EAU Guidelines on Neuro-Urology, 2015. [\n                    http:\/\/uroweb.org\/wp-content\/uploads\/21-Neuro-Urology_LR2.pdf\n                    \n                  ]."},{"issue":"2","key":"174_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167\u201378.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"174_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/nau.20870","volume":"29","author":"P Abrams","year":"2010","unstructured":"Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, Cottenden A, Davila W, De Ridder D, Dmochowski R, Drake M, Dubeau C, Fry C, Hanno P, Smith JH, Herschorn S, Hosker G, Kelleher C, Koelbl H, Khoury S, Madoff R, Milsom I, Moore K, Newman D, Nitti V, Norton C, Nygaard I, Payne C, Smith A, Staskin D, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213\u201340.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"174_CR19","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","volume":"184","author":"T Abdel-Meguid","year":"2010","unstructured":"Abdel-Meguid T. Botulinum toxin A injections into neurogenic overactive bladder-to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184(6):2423\u20138.","journal-title":"J Urol"},{"key":"174_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000350247","volume":"91","author":"V Samal","year":"2013","unstructured":"Samal V, Mecl J, Sram J. Submucosal Administration of OnabotulinumtoxinA in the treatment of Neurogenic Detrusor Overactivity: Pilot Single-Centre Experience and Comparison with standard injection into the Detrusor. Urology International. 2013;91:423\u20138.","journal-title":"Urology International"},{"issue":"8","key":"174_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.parkreldis.2010.06.006","volume":"16","author":"H Kulaksizoglu","year":"2010","unstructured":"Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons\u2019s disease. Parkinsonism Relat Disord. 2010;16(8):531\u20134.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"174_CR22","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","volume":"186","author":"A Giannantoni","year":"2011","unstructured":"Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, Porena M, Berardelli A. Botulinum toxin type A in patients with Parkinson\u2019s disease and refractory overactive bladder. J Urol. 2011;186(3):960\u20134.","journal-title":"J Urol"},{"issue":"1","key":"174_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","volume":"164","author":"B Schurch","year":"2000","unstructured":"Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol. 2000;164(1):692\u20137.","journal-title":"Preliminary results J Urol"},{"issue":"3","key":"174_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.juro.2010.05.035","volume":"184","author":"U Mehnert","year":"2010","unstructured":"Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184(3):1011\u20136.","journal-title":"J Urol"},{"issue":"1","key":"174_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100\u201319.","journal-title":"Eur Urol"},{"issue":"4","key":"174_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742\u201350.","journal-title":"Eur Urol"},{"issue":"6","key":"174_CR27","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1016\/j.juro.2008.08.030","volume":"180","author":"WM White","year":"2008","unstructured":"White WM, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol. 2008;180(6):2522\u20136.","journal-title":"J Urol"},{"issue":"5","key":"174_CR28","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/S0022-5347(05)67048-6","volume":"164","author":"I Araki","year":"2000","unstructured":"Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson\u2019s disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000;164(5):1640\u20133.","journal-title":"J Urol"},{"issue":"9","key":"174_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1056\/NEJM200003023420918","volume":"342","author":"B Schurch","year":"2000","unstructured":"Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665.","journal-title":"N Engl J Med"},{"issue":"5","key":"174_CR30","first-page":"3291","volume":"13","author":"A Lucioni","year":"2006","unstructured":"Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection. Can J Urol. 2006;13(5):3291\u20135.","journal-title":"Can J Urol"},{"issue":"2","key":"174_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00101-012-1992-6","volume":"61","author":"U W\u00fcllner","year":"2012","unstructured":"W\u00fcllner U, Standop J, Kaut O, Coenen V, Kalenka A, Wappler F. Parkinson\u2019s disease. Perioperative management and anesthesia. Anaesthesist. 2012;61(2):97\u2013105.","journal-title":"Anaesthesist"},{"issue":"5","key":"174_CR32","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.juro.2009.01.049","volume":"181","author":"B Roth","year":"2009","unstructured":"Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and parkinson\u2019s disease-should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209\u201313.","journal-title":"J Urol"},{"issue":"20","key":"174_CR33","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"WM Association","year":"2013","unstructured":"Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"174_CR34","unstructured":"International conference on harmonisation: Good clinical practice guideline. 1996 [\n                    http:\/\/www.ich.org\/products\/guidelines\/efficacy\/article\/efficacy-guidelines\n                    \n                  ]"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-016-0174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-016-0174-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-016-0174-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-016-0174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T10:06:25Z","timestamp":1487671585000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-016-0174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1186\/s12894-016-0174-2","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,5]]},"article-number":"55"}}